BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El Jabbour T, Lagana SM, Lee H. Update on hepatocellular carcinoma: Pathologists’ review. World J Gastroenterol 2019; 25(14): 1653-1665 [PMID: 31011252 DOI: 10.3748/wjg.v25.i14.1653] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Ziol M. [Liver tumor pathology seminar. Case 7]. Ann Pathol 2021;41:449-53. [PMID: 34420807 DOI: 10.1016/j.annpat.2021.02.009] [Reference Citation Analysis]
2 Gupta M, Akhtar J, Sarwat M. MicroRNAs: Regulators of immunological reactions in hepatocellular carcinoma. Semin Cell Dev Biol 2021:S1084-9521(21)00134-8. [PMID: 34049801 DOI: 10.1016/j.semcdb.2021.05.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Djokic M, Cemazar M, Bosnjak M, Dezman R, Badovinac D, Miklavcic D, Kos B, Stabuc M, Stabuc B, Jansa R, Popovic P, Smid LM, Sersa G, Trotovsek B. A Prospective Phase II Study Evaluating Intraoperative Electrochemotherapy of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3778. [PMID: 33333941 DOI: 10.3390/cancers12123778] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kim Y, Kim YS, Yoo JJ, Kim SG, Chin S, Moon A. Rare case of hepatocellular carcinoma metastasis to urinary bladder: A case report . World J Clin Cases 2022; 10(16): 5470-5478 [DOI: 10.12998/wjcc.v10.i16.5470] [Reference Citation Analysis]
5 Lubel JS, Roberts SK, Howell J, Ward J, Shackel NA. Current issues in the prevalence, diagnosis and management of hepatocellular carcinoma in Australia. Intern Med J 2021;51:181-8. [DOI: 10.1111/imj.15184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zheng W, Huang H, She D, Xiong M, Chen X, Lin X, Cao D. Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M. Abdom Radiol (NY) 2022;47:957-68. [PMID: 34964069 DOI: 10.1007/s00261-021-03380-6] [Reference Citation Analysis]
7 Huang Y, Ge W, Ding Y, Zhang L, Zhou J, Kong Y, Cui B, Gao B, Qian X, Wang W. The circular RNA circSLC7A11 functions as a mir-330-3p sponge to accelerate hepatocellular carcinoma progression by regulating cyclin-dependent kinase 1 expression. Cancer Cell Int 2021;21:636. [PMID: 34844614 DOI: 10.1186/s12935-021-02351-7] [Reference Citation Analysis]
8 Çolaklar A, Altınbaş NK. Infiltrative non-mass-like hepatocellular carcinoma initially presenting with isolated malignant portal vein thrombosis: A case report and review of the literature. J Ultrason 2020;20:e55-60. [PMID: 32320167 DOI: 10.15557/JoU.2020.0009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Bello HR, Mahdi ZK, Lui SK, Nandwana SB, Harri PA, Davarpanah AH. Hepatocellular Carcinoma With Atypical Imaging Features: Review of the Morphologic Hepatocellular Carcinoma Subtypes With Radiology-Pathology Correlation. J Magn Reson Imaging 2021. [PMID: 33682266 DOI: 10.1002/jmri.27553] [Reference Citation Analysis]
10 Zheng XS, Liu HJ, Zhang LL, Li H, Wang CJ, Xin YJ, Hao R. MiR-559 targets GP73 to suppress proliferation and invasion of hepatocellular carcinoma in vitro. Kaohsiung J Med Sci 2020;36:793-8. [PMID: 32492286 DOI: 10.1002/kjm2.12246] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Chen X, Liao L, Li Y, Huang H, Huang Q, Deng S. Screening and Functional Prediction of Key Candidate Genes in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Biomed Res Int 2020;2020:7653506. [PMID: 33102593 DOI: 10.1155/2020/7653506] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Zhao L, Yang Q, Liu J. Clinical Value Evaluation of microRNA-324-3p and Other Available Biomarkers in Patients With HBV Infection-Related Hepatocellular Carcinoma. Open Forum Infect Dis 2021;8:ofab108. [PMID: 34189151 DOI: 10.1093/ofid/ofab108] [Reference Citation Analysis]
13 Kong Y, Jing Y, Sun H, Zhou S, M.a B. The Diagnostic Value of Contrast-Enhanced Ultrasound and Enhanced CT Combined with Tumor Markers AFP and CA199 in Liver Cancer. Journal of Healthcare Engineering 2022;2022:1-10. [DOI: 10.1155/2022/5074571] [Reference Citation Analysis]
14 Chen X, Lu Y, Shi X, Han G, Zhang L, Ni C, Zhao J, Gao Y, Wang X. Epidemiological and Clinical Characteristics of Five Rare Pathological Subtypes of Hepatocellular Carcinoma. Front Oncol 2022;12:864106. [DOI: 10.3389/fonc.2022.864106] [Reference Citation Analysis]
15 Karadag Soylu N. Update on Hepatocellular Carcinoma: a Brief Review from Pathologist Standpoint. J Gastrointest Cancer 2020;51:1176-86. [PMID: 32844348 DOI: 10.1007/s12029-020-00499-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
16 Garcia PP, Albuquerque RM, Osório FMF, Couto CA, Lima AS, Vidigal PVT. B-RAF PROTEIN IMMUNOEXPRESSION IN HEPATOCELLULAR CARCINOMA DUE TO HEPATITIS C VIRUS RELATED CIRRHOSIS. Arq Gastroenterol 2021;58:419-23. [PMID: 34909843 DOI: 10.1590/S0004-2803.202100000-76] [Reference Citation Analysis]
17 Hu Y, Qiu W, Kong Z, Wu S, Liu Y, Zhu C, Qin X. LncRNA GSTM3TV2 Promotes Cell Proliferation and Invasion via miR-597/FOSL2 Axis in Hepatocellular Carcinoma. Biomed Res Int 2021;2021:3445970. [PMID: 34458365 DOI: 10.1155/2021/3445970] [Reference Citation Analysis]
18 Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of HCC in special populations. J Hepatol 2021;74:931-43. [PMID: 33248171 DOI: 10.1016/j.jhep.2020.11.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
19 Wang X, Li FY, Zhao W, Gao ZK, Shen B, Xu H, Cui YF. Long non-coding RNA GAS5 overexpression inhibits M2-like polarization of tumour-associated macrophages in SMCC-7721 cells by promoting PTEN expression. Int J Exp Pathol 2020;101:215-22. [PMID: 33146930 DOI: 10.1111/iep.12374] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
20 Wu X, Wang Q, Lu Y, Zhang J, Yin H, Yi Y. Clinical application of thioredoxin reductase as a novel biomarker in liver cancer. Sci Rep 2021;11:6069. [PMID: 33727662 DOI: 10.1038/s41598-021-85688-3] [Reference Citation Analysis]
21 Gou Q, Fu S, Xie Y, Zhang M, Shen Y. Treatment and Survival Patterns of Primary Adenosquamous Carcinoma of the Liver: A Retrospective Analysis. Front Oncol 2021;11:621594. [PMID: 34434888 DOI: 10.3389/fonc.2021.621594] [Reference Citation Analysis]
22 Razik A, Malla S, Goyal A, Gamanagatti S, Kandasamy D, Das CJ, Sharma R, Gupta AK. Unusual Primary Neoplasms of the Adult Liver: Review of Imaging Appearances and Differential Diagnosis. Curr Probl Diagn Radiol 2020:S0363-0188(20)30194-8. [PMID: 33199074 DOI: 10.1067/j.cpradiol.2020.10.001] [Reference Citation Analysis]
23 Ziogas IA, Hickman LA, Matsuoka LK, Izzy M, Montenovo MI, Rega SA, Feurer ID, Alexopoulos SP. Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates. Liver Transpl. 2020;26:1112-1120. [PMID: 32475062 DOI: 10.1002/lt.25807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
24 Jogi S, Varanai R, Bantu SS, Manne A. Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncol Rev 2020;14:515. [PMID: 33425223 DOI: 10.4081/oncol.2020.515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Kim C, Cigarroa N, Surabhi V, Ganeshan B, Pillai AK. Retrospective CT/MRI Texture Analysis of Rapidly Progressive Hepatocellular Carcinoma. J Pers Med 2020;10:E136. [PMID: 32967100 DOI: 10.3390/jpm10030136] [Reference Citation Analysis]
26 Pediconi N, Salerno D, Lupacchini L, Angrisani A, Peruzzi G, De Smaele E, Levrero M, Belloni L. EZH2, JMJD3, and UTX epigenetically regulate hepatic plasticity inducing retro-differentiation and proliferation of liver cells. Cell Death Dis 2019;10:518. [PMID: 31285428 DOI: 10.1038/s41419-019-1755-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
27 Li Y, Xiong H. Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways. BMC Cancer 2022;22:298. [PMID: 35313850 DOI: 10.1186/s12885-022-09398-3] [Reference Citation Analysis]
28 Wang QF, Wang QL, Cao MB. LncRNA PITPNA-AS1 as a Potential Diagnostic Marker and Therapeutic Target Promotes Hepatocellular Carcinoma Progression via Modulating miR-448/ROCK1 Axis. Front Med (Lausanne) 2021;8:668787. [PMID: 34055841 DOI: 10.3389/fmed.2021.668787] [Reference Citation Analysis]
29 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Lemekhova A, Hornuss D, Polychronidis G, Mayer P, Rupp C, Longerich T, Weiss KH, Büchler M, Mehrabi A, Hoffmann K. Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience. World J Surg Oncol 2020;18:93. [PMID: 32397993 DOI: 10.1186/s12957-020-01855-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Bao H, Muge Q. Anticancer effect of myristicin on hepatic carcinoma and related molecular mechanism. Pharm Biol 2021;59:1126-32. [PMID: 34410900 DOI: 10.1080/13880209.2021.1961825] [Reference Citation Analysis]
32 Qiu J, Xin Y. Incidence and prognosis of undifferentiated cancers of the digestive system: a population-based cohort study. Ann Transl Med 2021;9:15. [PMID: 33553308 DOI: 10.21037/atm-20-1615] [Reference Citation Analysis]
33 Tang B, Zhu J, Li J, Fan K, Gao Y, Cheng S, Kong C, Zheng L, Wu F, Weng Q, Lu C, Ji J. The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma. Cell Commun Signal 2020;18:174. [PMID: 33115468 DOI: 10.1186/s12964-020-00663-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
34 Xia F, Zhang Q, Huang Z, Ndhlovu E, Zhang M, Chen X, Zhang B, Zhu P. Effect of Perioperative Blood Transfusion on the Postoperative Prognosis of Ruptured Hepatocellular Carcinoma Patients With Different BCLC Stages: A Propensity Score Matching Analysis. Front Surg 2022;9:863790. [DOI: 10.3389/fsurg.2022.863790] [Reference Citation Analysis]
35 Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol 2021;74:1212-24. [PMID: 33545267 DOI: 10.1016/j.jhep.2021.01.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
36 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Cho SJ. Pediatric Liver Tumors: Updates in Classification. Surg Pathol Clin 2020;13:601-23. [PMID: 33183723 DOI: 10.1016/j.path.2020.09.002] [Reference Citation Analysis]
38 Kmeid M, Lukose G, Hodge K, Cho D, Kim KA, Lee H. Aberrant expression of SATB2, CDX2, CDH17 and CK20 in hepatocellular carcinoma: a pathological, clinical and outcome study. Histopathology 2021. [PMID: 34036629 DOI: 10.1111/his.14420] [Reference Citation Analysis]
39 Zhang D, Love T, Hao Y, Liu BL, Thung S, Fiel MI, Whitney-Miller CL, Liao X. Tumor Size, Not Small Vessel Invasion, Predicts Survival in Patients With Hepatocellular Carcinoma. Am J Clin Pathol 2022:aqac001. [PMID: 35142813 DOI: 10.1093/ajcp/aqac001] [Reference Citation Analysis]
40 Vij M, Calderaro J. Pathologic and molecular features of hepatocellular carcinoma: An update. World J Hepatol 2021; 13(4): 393-410 [PMID: 33959223 DOI: 10.4254/wjh.v13.i4.393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
41 Ren H, Wei ZC, Sun YX, Qiu CY, Zhang WJ, Zhang W, Liu T, Che X. ATF2-Induced Overexpression of lncRNA LINC00882, as a Novel Therapeutic Target, Accelerates Hepatocellular Carcinoma Progression via Sponging miR-214-3p to Upregulate CENPM. Front Oncol 2021;11:714264. [PMID: 34513693 DOI: 10.3389/fonc.2021.714264] [Reference Citation Analysis]
42 Li C, Pan XY, Ma M, Zhao J, Zhao F, Lv YP. Astragalus polysacharin inhibits hepatocellular carcinoma-like phenotypes in a murine HCC model through repression of M2 polarization of tumour-associated macrophages. Pharm Biol 2021;59:1533-9. [PMID: 34726570 DOI: 10.1080/13880209.2021.1991384] [Reference Citation Analysis]
43 Lachance E, Mandziuk J, Sergi CM, Bateman J, Low G. Radiologic-Pathologic Correlation of Liver Tumors. In: Sergi CM, editor. Liver Cancer. Exon Publications; 2021. pp. 87-108. [DOI: 10.36255/exonpublications.livercancer.2021.ch5] [Reference Citation Analysis]
44 Tang Y, Xu H, Dai Y, Wang F, Huang W, Liu P, Gu Y. A novel peptide targeting c-Met for hepatocellular carcinoma diagnosis. J Mater Chem B 2021;9:4577-86. [PMID: 34047746 DOI: 10.1039/d1tb00408e] [Reference Citation Analysis]
45 Sutthatarn P, Morin CE, Gartrell J, Furman WL, Langham MR, Santiago T, Murphy AJ. Bilateral Diffuse Nodular Pulmonary Ossification Mimicking Metastatic Disease in a Patient with Fibrolamellar Hepatocellular Carcinoma. Children (Basel) 2021;8:226. [PMID: 33809687 DOI: 10.3390/children8030226] [Reference Citation Analysis]